

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	hours per response:
	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Schor Chen</u>  (Last) (First) (Middle) C/O ADICET BIO, INC. 200 BERKELEY STREET, 19TH FLOOR  (Street) BOSTON MA 02116  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Adicet Bio, Inc. [ ACET ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President & CEO
	3. Date of Earliest Transaction (Month/Day/Year) 09/09/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/09/2022		s <sup>(1)</sup>		8,094	D	\$16.5062 <sup>(2)</sup>	66,747	I	See Footnote <sup>(3)</sup>
Common Stock	09/12/2022		s <sup>(1)</sup>		66,747	D	\$16.7694 <sup>(4)</sup>	0	I	See Footnote <sup>(3)</sup>
Common Stock	09/12/2022		s <sup>(1)</sup>		200	D	\$18	143,060	I	See Footnote <sup>(5)</sup>
Common Stock	09/13/2022		s <sup>(1)</sup>		3,371	D	\$18.0105 <sup>(6)</sup>	139,689	I	See Footnote <sup>(5)</sup>
Common Stock								122,712	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$16.50 to \$16.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request.
- Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$16.50 to \$16.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$18.00 to \$18.05, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

**Remarks:**

/s/ Nick Harvey, Attorney-in-Fact 09/13/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.